---
title: "These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292904673.md"
description: "Elevance Health reported strong Q2 earnings, beating estimates with $7.45 adjusted EPS and $49.83 billion revenue, while raising full-year guidance. Following the announcement, analysts revised price targets: Baird raised to $393, Guggenheim raised to $455, and Barclays lowered to $457, though ratings remained largely unchanged."
datetime: "2026-07-16T12:17:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292904673.md)
  - [en](https://longbridge.com/en/news/292904673.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292904673.md)
---

# These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

**Elevance Health Inc.** (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.

Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21. Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.

Elevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91. The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.

Elevance Health shares rose 1.8% to $397.20 in pre-market trading.

These analysts made changes to their price targets on Elevance Health following earnings announcement.

-   Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.
-   Barclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.
-   Guggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.

**Considering buying ELV stock? Here’s what analysts think:**

_Photo via Shutterstock_

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [How Mixed Q2 Earnings and Higher EPS Guidance Will Impact Elevance Health (ELV) Investors](https://longbridge.com/en/news/294124186.md)
- [Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey | ELV Stock News](https://longbridge.com/en/news/294391678.md)
- [Elevance Health, Inc. $ELV Shares Acquired by Cetera Investment Advisers](https://longbridge.com/en/news/293896171.md)
- [Elevance Health, Inc. $ELV Shares Acquired by Sei Investments Co.](https://longbridge.com/en/news/293841088.md)
- [Bessemer Group Inc. Has $1.26 Million Holdings in Elevance Health, Inc. $ELV](https://longbridge.com/en/news/293717109.md)